SignaBlok to Present Preclinical Data on TREM-1-Targeting Drug for the Treatment of Sepsis, Pulmonary Inflammation and Fibrosis at the Respiratory Innovation Summit (RIS) and American Thoracic Society (ATS) International Conference 2025

 SignaBlok will present groundbreaking positive preclinical data detailing therapeutic activity of its leading macrophage-restricted TREM-1 inhibitor in experimental sepsis, acute respiratory distress syndrome (ARDS), and pulmonary fibrosis (PF) at the RIS and ATS Conference in San Francisco, California from May 16-21, 2025.

Shrewsbury, MA, March 24, 2025 – SignaBlok, Inc., a preclinical stage biotechnology company pioneering first-in-class, new mechanism-based peptide therapies for multiple diseases, today announced it will present positive preclinical data detailing therapeutic activity of its leading macrophage-restricted TREM-1 inhibitor in experimental sepsis, acute respiratory distress syndrome (ARDS), and pulmonary fibrosis (PF) at the RIS and ATS Conference in San Francisco, California from May 16-21, 2025.

Details on SignaBlok’s upcoming 2025 RIS and ATS poster presentations are as follows:

• In septic animals, TREM-1 blockade by SignaBlok's first-in-class macrophage-restricted TREM-1 inhibitor protects from death with the level of protection not declining at delayed treatment times

• In rats, macrophage-restricted TREM-1 blockade significantly reduces lipopolysaccharide (LPS)-induced neutrophil accumulation in the lungs when injected after, but not before, LPS challenge

• In mice with bleomycin-induced pulmonary fibrosis,TREM-1 blockade reduces the rate of progression and reverses fibrosis in the prevention and treatment models

• Data highlight potential of SignaBlok’s SCHOOL technology platform to support clinical development of TREM-1 drug with minimal risk of failure due to a new mechanism of action

Respiratory Innovation Summit:
Poster Title: Sepsis: Understanding Nature. Solving the Inflammation Puzzle. Saving Lives.
Presenter: Alexander B. Sigalov, Ph.D. (SignaBlok President and Principal Investigator)
Date / Time: Friday May 16, 2025 2 PM - Saturday May 17, 2025, 6 pm ATS International Conference:
Poster Title: Ligand-Independent TREM-1 Blockade Ameliorates Pulmonary Inflammation and Fibrosis
Presenter: Alexander B. Sigalov, Ph.D. (SignaBlok President and Principal Investigator)
Abstract Presentation Number: 9150
Session: A22 – Break on through: Airway epithelial barrier in inflammation and injury
Date / Time: Sunday May 18, 2025, 9:15 am – 11:15 am

About TREM-1
Triggering receptor expressed on myeloid cells 1 (TREM-1) serves as an inflammation amplifier. As such, TREM-1 is involved in the pathogenesis of sepsis, ARDS, PF, and other inflammatory pathologies. Clinical targeting of TREM-1 is challenging due to multiple known and still unidentified TREM-1 ligands.

About SignaBlok
SignaBlok, Inc. is a Massachusetts-based biotechnology company founded in 2009 to develop innovative, first-in-class therapeutics for targeted treatment of inflammation-associated diseases through the use of two key SignaBlok's proprietary technologies: 1) new mechanism-based approach to inhibition of cell receptors by using innovative, ligand-independent inhibitory peptides (the so-called SCHOOL peptides, the abbreviation coming from the "Signaling Chain HOmoOLigomerization" model of immune signaling); and 2) nature-inspired, multifunctional nanotechnology for targeted drug and/or imaging agent delivery to macrophages. Additional information about SignaBlok is available at www.signablok.com.

Signablok, Inc. To Present Preclinical Data on Trem-1-Targeting Drug for the Treatment of Cancer at the American Association for Cancer Research Annual Meeting 2025

 SignaBlok, Inc. will present groundbreaking preclinical data on targeting innate inflammation for the treatment of hard-to-treat cancers. In combination with standard-of-care chemotherapy, SignaBlok's new mechanism-based inhibitor of TREM-1, an inflammation amplifier, prevents cancer recurrence, improves complete response rate and survival in experimental pancreatic cancer. In combination with anti-PD-L1 treatment, it overcomes pancreatic cancer resistance to immunotherapy.

Shrewsbury, MA, USA, March 23, 2025 –  SignaBlok, Inc.. a preclinical stage biotechnology company pioneering first-in-class, new mechanism-based peptide therapies for multiple diseases, today announced it will present positive preclinical oncology data on the company's leading macrophage-restricted TREM-1 inhibitor at the 2025 AACR Annual Meeting to be held in Chicago, Illinois from April 25-30, 2025.

Details on SignaBlok’s upcoming 2025 AACR Annual Meeting poster presentation are as follows:

• In experimental pancreatic cancer, SignaBlok's first-in-class macrophage-restricted TREM-1 inhibitor:
− prevents cancer recurrence, improves complete response rate and survival, when administered after, but not concurrently with, standard-of-care chemotherapy

− reverses immunosuppression and overcomes cancer resistance to anti-PD-L1 immunotherapy

• Rodent studies indicate that SignaBlok's TREM-1 inhibitor is safe and well-tolerable

• Data highlight potential of SignaBlok’s SCHOOL technology platform to support clinical development of TREM-1 drug with minimal risk of failure due to a new mechanism of action

• Presented results have important clinical implications in the treatment of patients with not only pancreatic cancer, but also other inflammation-associated, hard-to-treat solid tumors

Poster Title: Timely resolution of TREM-1-mediated inflammation after chemotherapy improves complete response rate and survival in experimental pancreatic cancer
Presenter: Alexander B. Sigalov, Ph.D. (SignaBlok, Inc.; President and Principal Investigator)
Abstract Presentation Number: LB128
Poster Session 52: Monday April 28, 2025, 9:00 am – 12:00 pm

About pancreatic cancer (PC)
PC is the third leading cause of cancer-related death in the US. Despite recent advances, the 5-year survival rate for all stages combined is as low as 13%, necessitating the development of new approaches.

About TREM-1
Triggering receptor expressed on myeloid cells 1 (TREM-1) serves as an inflammation amplifier. As such, TREM-1 is critically involved in the pathogenesis of multiple cancer types, sepsis, rheumatoid arthritis, acute respiratory distress syndrome, scleroderma, atherosclerosis, and other inflammatory pathologies. Clinical targeting of TREM-1 is challenging due to multiple known and still unidentified TREM-1 ligands.

About SignaBlok
SignaBlok, Inc. is a Massachusetts-based biotechnology company founded in 2009 to develop innovative, first-in-class therapeutics for targeted treatment of inflammation-associated diseases through the use of two key SignaBlok's proprietary technologies: 1) new mechanism-based approach to inhibition of cell receptors by using innovative, ligand-independent inhibitory peptides (the so-called SCHOOL peptides, the abbreviation coming from the "Signaling Chain HOmoOLigomerization" model of immune signaling); and 2) nature-inspired, multifunctional nanotechnology for targeted drug and/or imaging agent delivery to macrophages. Additional information about SignaBlok is available at www.signablok.com.

Acclaimed Author A.M. Berkowitz Featured in Reader’s House Magazine

 Renowned children’s author A.M. Berkowitz has been featured in the latest issue of Reader’s House Magazine, London’s premier literary gateway.

 

London, UK, March 8, 2025 – Renowned children’s author A.M. Berkowitz has been featured in the latest issue of Reader’s House Magazine, London’s premier literary gateway.

Recognised for her exceptional storytelling and ability to inspire young readers, Berkowitz was also honoured with the Editor’s Choice Award of Literary Excellence, a prestigious accolade presented to a select group of outstanding authors.

Reader’s House Magazine, which is available in over 190 countries and thousands of stores including Amazon, Barnes & Noble, Walmart, and Waterstones, praised both Berkowitz and her literary works. Best known for the Gigglet the Happy Little Piglet series, her stories spark imagination, joy, and a love for reading among children worldwide.

In an exclusive interview, Berkowitz shared her heartfelt journey from a corporate career and operatic background to becoming a celebrated children’s author. Reflecting on her transition, she said: “I discovered my passion for writing children’s books was undeniable and would happen whether or not it was in ‘my plan.’”

The interview delves into the inspiration behind her beloved character, Gigglet, whose adventures have captivated young audiences. Berkowitz revealed that the idea for Gigglet came to her unexpectedly:

“One morning, I received a spam email that said ‘Lit Gadget’ in the subject line, but my brain read it as ‘Gigglet.’ I laughed out loud and thought, ‘That doesn’t say Gigglet, but what if it did?’ And from there, a whole world opened up.”

Berkowitz’s books are more than just stories—they encourage creativity, fun, and a deep sense of connection. Speaking about her mission, she shared: “The most important thing to remember when reading the Gigglet books is to be in the moment, have fun, follow your bliss, and ‘GET YOUR GIGGLE ON.’”

With multiple new books and exciting projects on the horizon, including the expansion of the Gigglet series, Berkowitz continues to inspire children and families worldwide.
The full interview is available in Reader’s House Magazine, Issue 49 at https://readershouse.co.uk/issue-49.



About A.M. Berkowitz
A.M. Berkowitz is a celebrated children’s author known for her imaginative and heartwarming storytelling. A former operatic mezzo-soprano and corporate professional, she found her true passion in writing, creating the beloved Gigglet the Happy Little Piglet series. Through her books, Berkowitz aims to inspire joy, creativity, and a love for reading in children worldwide. Visit her website at www.ambkidsbooks.com for more information on her work and upcoming projects.

MovPilot Introduces a New Solution for Offline Streaming — Paramount Plus Video Downloader

 MovPilot Paramount Plus Video Downloader lets user download videos in MP4/MKV formats with up to 85% off for a limited time. Enjoy fast, offline viewing with multilingual support and metadata preservation. Easily save Paramount+ movies with subtitles and no ads.

HONGKONG, CHINA – March 05, 2025 - /PressReleasePoint/ – With the ever-increasing demand for seamless offline streaming, MovPilot has introduced its latest innovation—the Paramount Plus Video Downloader. This newly launched software is designed to provide a reliable solution for those who seek high-quality offline access to their favorite Paramount Plus content.

MovPilot – Meeting the Growing Demand for Offline Streaming
The digital entertainment landscape continues to evolve, with audiences expecting greater flexibility in how they watch their favorite shows and movies. Streaming platforms offer extensive content libraries, but internet connectivity issues and platform restrictions often limit viewing experiences. Recognizing this need, MovPilot has developed a Paramount Plus Video Downloader that allows users to download and enjoy Paramount Plus content anytime, anywhere, without limitations.
This software is built with a focus on efficiency, ensuring that high-resolution videos can be stored securely for offline playback. By bridging the gap between streaming convenience and offline accessibility, MovPilot provides a solution tailored to modern entertainment habits.

Key Features of MovPilot Paramount Plus Video Downloader
The MovPilot Paramount Plus Video Downloader is equipped with a range of features designed to enhance the downloading and viewing experience:

• High-Quality Downloads – Supports up to 1080p full HD resolution, ensuring that videos retain excellent visual clarity.

• DRM-Free Format Choices – Store videos in MP4 or MKV format, ensuring compatibility with all devices and media players.

• Subtitles and Audio Tracks Preservation – Maintains multiple language options for subtitles and audio tracks, catering to diverse viewer preferences.

• Ad-Free Playback – Downloads videos without advertisements, allowing uninterrupted entertainment.

• Fast and Stable Performance – Utilizes advanced technology to ensure quick 5X faster and reliable downloads with minimal buffering.

• Compatibility with Multiple Devices – Enables seamless transfer and playback across Windows, Mac, smartphones, and tablets.

By incorporating these features, MovPilot ensures that Paramount Plus subscribers have an optimal offline viewing experience, free from the constraints of an active internet connection.

Pricing Plans and Special Promotions
MovPilot Paramount Plus Video Downloader is available at competitive pricing, ensuring accessibility for various streaming needs. To celebrate the launch, limited-time discounts are being offered across different subscription plans and bundled options.

1. Standard Plans for MovPilot Paramount Plus and Other Platforms

For those who require a downloader for a single streaming service like Paramount+, Netflix, Amazon Prime, Disney+, HBO Max, and Hulu, MovPilot offers flexible plans:

• 1-Month Plan – Originally priced at $39.95, now available at $35.96 (10% OFF).

• 1-Year Plan – A significant discount of 85% OFF, bringing the price down to $59.95 (just $4.99/month).

 

2. MovPilot All-in-One Video Downloader

For users seeking a comprehensive solution, MovPilot’s all-in-one downloader supports multiple platforms, including Netflix, Amazon Prime, Disney+, HBO Max, Hulu, and Paramount Plus:

• 1-Month Plan – Reduced from $49.95 to $44.95 (10% OFF).

• 1-Year Plan – Enjoy 80% OFF, making it just $99.95 ($8.33/month).

• Perpetual Plan – A one-time payment of $134.95 (10% OFF, originally $149.95) ensures lifetime access.

 

3. Special Bundle Offers

For users managing multiple streaming subscriptions, MovPilot offers discounted bundle deals, combining two services at once:

• Netflix + Amazon Prime Downloader – 35% OFF, now $116.94 (was $179.90).

• Disney Plus + Hulu Downloader – 35% OFF, now $116.94 (was $179.90).

• Netflix + Paramount Plus Downloader – 30% OFF, now $125.93 (was $179.90).

These promotional prices are available for a limited time, providing an excellent opportunity for users to secure uninterrupted offline access to their favorite content at the best possible value.

How to Get Started with MovPilot Paramount Plus Video Downloader
Getting started with MovPilot is simple and requires only a few steps:

1. Download and Install – Install the MovPilot Paramount Plus Video Downloader from the official website.

2. Log in to Paramount Plus – Launch the software and sign in to a valid Paramount Plus account.

3. Search for Content – Use the built-in search function to find the desired movies or TV shows.

4. Select Download Preferences – Choose the preferred resolution, subtitle settings, and audio tracks.

5. Start Downloading – Click the download button and enjoy seamless offline playback once the process is complete.

The intuitive design of the software ensures that even first-time users can navigate the process with ease.

A Valuable Tool for Offline Streaming Enthusiasts

For those who frequently travel, experience unstable internet connections, or simply wish to build a personal offline library of Paramount Plus content, the MovPilot Paramount Plus Video Downloader serves as a highly valuable tool. By offering high-definition downloads, customizable playback options, and an ad-free experience, this software caters to modern streaming preferences with efficiency and reliability.
As the demand for offline viewing solutions continues to rise, MovPilot remains committed to delivering user-friendly, high-performance software that enhances digital entertainment experiences. Take advantage of MovPilot special promotions today and enhance the streaming experience!

About MovPilot
MovPilot is a leading software developer specializing in high-quality video download solutions for popular streaming platforms. With a mission to provide seamless offline viewing experiences, MovPilot continuously innovates to meet the evolving demands of digital entertainment. The company's products are known for their efficiency, reliability, and ease of use, making MovPilot a trusted choice for streaming enthusiasts worldwide.